Targeting Bladder Cancer
The first FGFR-targeted anticancer therapeutic to be approved by the FDA, erdafitinib, is intended for use in the treatment...
Progress Against Cancer
The first FGFR-targeted anticancer therapeutic to be approved by the FDA, erdafitinib, is intended for use in the treatment...
Adding the immunotherapeutic atezolizumab to standard chemotherapy improved overall survival for patients with extensive-stage small-cell lung cancer. The U.S....
The FDA approval is for the use of atezolizumab in combination with Abraxane for the treatment of certain patients...
The molecularly targeted therapeutic tagraxofusp-erzs is the first ever treatment approved by the FDA for the treatment of blastic...
The FDA approval of calaspargase pegol-mknl provides a longer-acting chemotherapy option for certain patients with acute lymphoblastic leukemia. The...
The FDA approval of pembrolizumab for treating certain patients with Merkel cell carcinoma makes it the second immunotherapeutic approved...
The FDA approval of gilteritinib provides a new treatment option for certain patients whose acute myeloid leukemia tests positive...
The FDA approval makes larotrectinib the first molecularly targeted therapeutic approved for use based on a tumor biomarker rather...
The FDA recently approved two molecularly targeted therapeutics for treating patients newly diagnosed with acute myeloid leukemia (AML) who...
The FDA approval of pembrolizumab for treating certain patients with liver cancer makes it the second immunotherapeutic approved for...